ANZGOG Preceptorship 2026 | Ovarian Cancer

Co-Chairs: Dr Catherine Shannon, Prof Kylie Gorringe & A/Prof Rhonda Farrell

Friday 20 November 2026 | 12.00pm – 5.05pm (AEDT)
Saturday 21 November 2026 | 10.30am – 12.40pm (AEDT)

***Each talk will be 10 mins pre-recorded with Live Q&A.**

12.00pm–12.05pm	**WELCOME**	
12.05pm–12.20pm 15min	**How to get involved with ANZGOG clinical trials – mentoring new researchers.** *- John Andrews, ANZGOG Research Manager* **5 min Q&A**	
12.20pm – 2.00pm 100 minutes	**SESSION 1: RARE CANCERS** (2min Introduction)	
	Mentors: **Dr Connie Diakos** **Dr Nivi Rajadevan** **Prof Anna deFazio AM**	**LOW GRADE SEROUS** **Talk 1: Primary systemic therapy in low-grade serous ovarian cancer - who needs, what should it be, in what order?** *- Teesha Downton, MO Specialist, NT* **2.5 mins Q&A** **Talk 2: Recurrent low-grade serous ovarian cancer – would surgery be considered or is it time for systemic therapy?** *- Laura Panozzo, MO Trainee, VIC* **2.5 mins Q&A** **Talk 3: What are the most commonly altered molecular pathways in low-grade serous ovarian carcinoma and can they be targeted therapeutically?** *- Zarka Samoon, MO/PhD Candidate, VIC* **2.5 mins Q&A**
	Panel Discussion with mentors and presenters (10mins)	
	Mentors: **Dr Michelle Wilson** **Dr Nicola Meagher** **Dr Felicia Roncolato**	**Talk 4: What is Small Cell Carcinoma of the Ovary, Hypercalcemic Type [SCCOHT] and how do you treat it?** *- Elizabeth Weeda, MO Trainee, VIC* **2.5 mins Q&A** **Talk 5: When should Stage I MOC receive chemotherapy?** *- Mandy Wang, GO Fellow, NSW* **2.5 mins Q&A** **Talk 6: Clear Cell Ovarian Cancer – Discuss the evidence for use of immune therapies** *-Josie Wright, GO Registrar, ACT* **2.5 mins Q&A**
	Panel Discussion with mentors and presenters (10mins)	
2.00pm – 2.05pm	**5min Break**	

2.05pm – 3.45pm **100mins**	**SESSION 2: MEDICAL ONCOLOGY** (2min Introduction)	
	Mentors: **Dr Catherine Shannon**	**Talk 7: Beyond BRCA and homologous recombination deficiency, what molecular pathways represent promising therapeutic targets in high-grade serous ovarian cancer? Discuss emerging targets and how molecular understanding of HGSOC may lead to new treatment strategies.** (Not ADCs. first line.) *- Sarah Banting, GO Registrar, VIC* **2.5 mins Q&A**
	Dr Alicia Didsbury	**Talk 8: Immunotherapy has been less successful in high-grade serous ovarian cancer than in other solid tumours. What are emerging strategies to overcome this?** *- Wei Loh, GO Registrar, NSW* **2.5 mins Q&A**
	Dr Michelle Harrison	**Talk 9: What would be considered contemporary SOC treatment options for PROC. What information drives treatment decisions? (Non-ADC)** *- Chloe Higgins, GO Trainee, TAS* **2.5 mins Q&A**
	Panel Discussion with mentors and presenters (10mins)	
	Mentors: **Dr Nikki Burdett**	**Talk 10: How does resistance to PARP inhibitors develop? Discuss implications for clinical practice and opportunities for intervention** *- Maddy Jones, GO Registrar, VIC* **2.5 mins Q&A**
	Dr Michelle Harrison	**Talk 11: Discuss the impact of treatments post PARPi with reference to progression during or after PARPi therapy. Is there any role for PARPi after PARPi?** *- Hannah Laws, GO Registrar, Christchurch, NZ* **2.5 mins Q&A**
	A/Prof Kate Webber	**Talk 12: How do we define platinum sensitive, platinum resistant and platinum refractory disease in the post PARPi era. Why does it matter?** *- Laura Sunderland, GO Registrar, NSW* **2.5 mins Q&A**
	Panel Discussion with mentors and presenters (10mins)	
3.45pm – 3.50pm	**5 min Break**	
3.50pm – 5.05pm **75mins**	**SESSION 3: PATHOLOGY** (2min introduction)	
	Mentors: **Prof Rosemary Balleine**	**Talk 13: Co-existent low-grade endometrioid ovarian cancer and endometroid endometrial cancer - are these the one primary with metastases to the other or two separate primaries?** *- David O'Keefe, GO Registrar, VIC* **2.5 mins Q&A**

	A/Prof Lyndal Anderson	**Talk 14: Discuss the pathology testing and significance of folate receptor alpha in high grade serous adenocarcinoma of ovary.** *- Mandy Wang, GO Fellow, NSW* **2.5 mins Q&A**
	Dr Gwo-Yaw Ho	**Talk 15: Ovarian carcinosarcoma contains both epithelial (carcinomatous) and mesenchymal (sarcomatous) components. Are these distinct tumour populations or different states of the same tumour clone, and what does our understanding of their relationship mean for how carcinosarcoma should be classified and treated?** *- Dasuni Pathiraja, GO Fellow, NSW* **2.5 mins Q&A**
	Prof Kylie Gorringe	**Talk 16: How do you distinguish advanced primary MOC from metastases from elsewhere?** *-Sita Murugappan, GO Fellow, VIC* **2.5 mins Q&A**
	A/Prof Yoland Antill	**Talk 17: What are the cellular origins of different epithelial ovarian cancer histotypes and how does this affect prevention strategies?** *- Danielle Christmas, GO Fellow, NSW* **2.5 mins Q&A**
	Panel Discussion with mentors and presenters (10 mins)	
5.05pm	**CLOSING**	

Day 2 – Saturday 10.30am – 12.40pm AEDT		
10.30am – 10.35am	**WELCOME**	
10.35am – 11.50am 75mins	**SESSION 4: SURGICAL** (2min introduction)	
	Mentors: **Dr Nivi Rajadevan**	**Talk 18: What is the evidence for R0 versus leaving sub-centimetre disease in women having surgery for primary HGSC? Is this decision influenced by BRCA or HRD status?** *- Zarka Samoon, MO/PhD Candidate, VIC* **2.5 mins Q&A**
	Dr Michael Burling	**Talk 19: What is the role of lymph node dissection in early and advanced ovarian cancer?** *- Nmezi Davidson, MO Trainee, ACT* **2.5 mins Q&A**
	Prof Paul Cohen	**Talk 20: In regard to risk-reducing surgery in gBRCA mutation carriers:** • **What is the evidence for hysterectomy at the time of risk reducing surgery to reduce cancer risk in BRCA carriers?**

		• **If an incidental serous tubal intraepithelial carcinoma is found, what is the role for further surgery, chemotherapy or surveillance?** *- Teesha Downton, MO Specialist, NT* **2.5 mins Q&A**
	Dr Bryony Simcock	**Talk 21: Discuss the role of the different modalities available to assess suitability for cytoreduction in primary and recurrent advanced intra-abdominal malignancy (including imaging and laparoscopy).** *- Kevin Chow, MO Fellow, VIC* **2.5 mins Q&A**
	Dr Rhett Morton	**Talk 22: Is there any survival benefit to cytoreductive surgery following more than 4 cycles of chemotherapy in the first line setting for high grade serous cancer of OTP or endometrium?** *- Natalie Chilko, MO Trainee, VIC* **2.5 mins Q&A**
	Panel Discussion with mentors and presenters (10 mins)	
11.50am – 12.40pm 50mins	**SESSION 6: SURVIVORSHIP & QUALITY OF LIFE** (2min Introduction)	
	Mentors: **Prof Alison Brand AM**	**Talk 23: What is the role of exercise therapy during and following chemotherapy for ovarian cancer, and how will you support them to commence / maintain exercise therapy? –** (and how do we compare it to other cancers, compare with Challenge Trial) *- Joanna Ho, GO Trainee, WA* **2.5 mins Q&A**
	Prof Sandi Hayes	**Talk 24: What should a trainee know about screening for psychological distress and fear of cancer recurrence, and when to manage this within the treating team versus escalate to specialist support?** *- Danielle Christmas, GO Fellow, NSW* **2.5 mins Q&A**
	A/Prof Alison Davis	**Talk 25: As more women live for years with recurrent or chronic ovarian cancer, how should our model of survivorship care and follow-up adapt to this reality?** *- Nicole Song, GO Registrar, Auckland, NZ* **2.5 mins Q&A**
	10 mins	**Panel Discussion with mentors and presenters**
12.40pm	**CLOSING**	